Cardax, Inc.
CDXI 0.00 Stock Price Cardax, Inc.

Home
  /  
Stock List  /  Cardax, Inc.
Range:1.0E-6-2.0E-4Vol Avg:3Last Div:0Changes:0
Beta:-13.76Cap:0.00BCurrency:USDExchange:PNK
Sector:HealthcareIPO:Wed Mar 06 2013Empoloyees:10
CUSIP:14141D201CIK:0001544238ISIN:US14141D2018Country:US
CEO:Mr. David G. WatumullWebsite:https://www.cardaxpharma.com
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

Stock Details

The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
DMCA.com Protection StatusPowered by StackThrow